Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease

NCT04154072 is registered in ClinicalTrials.gov with Neuraly, Inc. as lead sponsor.

NCT NCT04154072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04154072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease
Lead sponsor
Neuraly, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 27, 2020
Completion date
February 14, 2023
Enrollment
255 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease